Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience (NASDAQ: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders treatments, has scheduled its Q1 2025 earnings conference call for May 8th, 2025, at 1:30 PM PT/4:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Skye Bioscience (NASDAQ: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders treatments, has scheduled its Q1 2025 earnings conference call for May 8th, 2025, at 1:30 PM PT/4:30 PM ET. The company will release its financial results after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation through Skye's Investor Relations website. A replay and transcript will be available post-call on the same platform.
Details
News Market Reaction – SKYE
The recorded move for SKYE in the trading session of this news was -1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.